Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection at a time when intervention can bring the greatest impact for patients.
Nucleix is aiming to treat cancer by detecting the disease earlier, at a time when intervention will have the most impact for patients.
Nucleix was founded in 2008 by Elon A. Ganor, Danny Frumkin, and Adam Wasserstrom. The company is headquartered in Rehovot, Merkaz, Israel.
Nucleix leverages NGS and PCR-based epigenetics to pioneer testing approach that uses methylation-based identification for early-stage and recurring cancer detection.
Nucleix's non-invasive EpiCheck® platform delivers highly accurate and sensitive results, all while providing a seamless testing option for patients and the healthcare system.
Nucleix is building an EpiCheck franchise, beginning with the Bladder EpiCheck® testing kit, marketed in Europe for bladder cancer recurrence. The Company is advancing a Lung EpiCheck test toward commercialization for high-risk individuals, while advancing additional tests for high-risk diseases.
Nucleix is backed by RA Capital Management, BlackRock, OrbiMed, Sands Capital, Lilly Asia Ventures, LYFE Capital, Aurum Ventures, DSC Investment and others. The company raised an additional $22M in financing on Jan 05, 2022. This brings Nucleix's total funding to $83M to date.